ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that the USDA has issued a product license for Dual-Force™ First Defense®.
Dual-Force™ in a single-dose oral syringe provides guaranteed levels of E. coli and coronavirus antibodies to prevent scours in newborn calves. The gel tube delivery format is a preferred administration route for some, as an alternative to the Company’s longstanding First Defense® capsule.
“Our goal is to formulate our efficacious colostrum antibodies into a variety of formats so that our customers can choose the option that works best for their operations,” commented Michael F. Brigham, President and CEO. “This regulatory validation should help us compete more effectively in the market and grow sales.”
“Quicker and easier administration is what we were aiming for when we made the decision to formulate our E. coli and coronavirus antibodies into a gel tube,” added Ms. Bobbi Jo Brockmann, Vice President of Sales and Marketing. “This product offers a non-digestible blue dye that serves as a marker, turning the calf’s first stool after administration neon blue-green to help detect and prevent protocol drift.”
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell has developed products that provide Immediate Immunity™ to newborn dairy and beef livestock. The Company is developing a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at: http://www.immucell.com.